8-K: Metagenomi Announces Positive Preclinical Data for Hemophilia A Gene Therapy Program

Metagenomi reports sustained Factor VIII activity in non-human primates for over 16 months, with its lead candidate, MGX-001, showing higher activity than wild-type FVIII.

Summary

• Metagenomi presented updated preclinical data for its hemophilia A program at the American Society of Hematology (ASH) 66th Annual Meeting.
• The data demonstrates sustained Factor VIII (FVIII) activity in non-human primates (NHP) for over 16 months.
• The company's lead development candidate, MGX-001, a bioengineered FVIII construct, showed higher FVIII activity compared to wild-type FVIII at similar integration rates.
• The study used a cynomolgus version of the FVIII gene (cFVIII) administered via AAV at a dose of 2.0E13 vg/kg, followed by an LNP at 1.0 mg/kg delivering the MG29-1 nuclease mRNA and associated guide RNA.
• Mean FVIII activity in the NHP study was maintained over the 16-month period, with levels at the 16.5-month time point at 72%, 9%, and 30% in each of the three animals.
• The FVIII knock-in was achieved with only transient elevation of liver transaminases and no other safety findings.
• MGX-001 showed no identifiable off-target editing in a series of assays.

Sentiment

Score: 8

Explanation: The document presents very positive preclinical data with strong efficacy and safety signals, suggesting a promising future for the company's hemophilia A program. The 16-month durability data is particularly encouraging.

Positives

• The study demonstrates durable FVIII activity over 16 months in an ongoing NHP study.
• MGX-001 achieved higher levels of FVIII activity versus wild type FVIII.
• The bioengineered construct may enable therapeutic FVIII activity at lower AAV doses with potential safety benefits.
• There were no significant safety findings, such as changes in albumin or bilirubin levels.
• The program is on track for an IND filing in 2026.

Risks

• The company's forward-looking statements are subject to risks and uncertainties that could negatively affect the business, operating results, financial condition, and stock value.
• Risks include the ability to obtain and maintain financing, the results of research and development activities, the timing of clinical trials, and dependence on third-party suppliers.
• The company is in the early stages of product development and requires substantial additional funds.

Future Outlook

The company is progressing MGX-001 towards the clinic and plans to file an IND in 2026.

Management Comments

• MGX-001 represents a potentially one-time curative treatment for both adults and children, with the goal to change the treatment paradigm for patients living with hemophilia A, said Brian C. Thomas, PhD, CEO and Founder of Metagenomi.

Industry Context

This announcement is significant in the gene therapy space, particularly for hemophilia A, where there is a need for more effective and durable treatments. Metagenomi's approach of precise in vivo integration of the FVIII gene is a differentiating factor compared to conventional gene therapies.

Comparison to Industry Standards

• The results are promising compared to traditional gene therapies for hemophilia A, which often struggle with durability and require high doses of viral vectors.
• Companies like BioMarin and Sangamo Therapeutics have also been developing gene therapies for hemophilia A, but Metagenomi's approach of using a bioengineered FVIII construct with precise in vivo integration could offer a competitive advantage.
• The 16-month durability data is notable, as many gene therapies show a decline in efficacy over time.

Stakeholder Impact

• The positive results are likely to be well-received by shareholders.
• The potential for a one-time curative treatment could significantly improve the lives of patients with hemophilia A.
• The company's employees may be motivated by the progress of the program.

Next Steps

• The company will continue to progress MGX-001 towards the clinic.
• The company plans to file an IND in 2026.

Key Dates

Keywords

Hemophilia A, Gene Editing, Factor VIII, MGX-001, Preclinical Data, Non-Human Primate, Gene Therapy, Metagenomi, ASH, AAV, LNP